PMC9 THE OPTIMAL COST-EFFECTIVENESS RATIO THRESHOLD IN CASE OF CO-MORBIDITIES  by Jakubczyk, MK et al.
A67Abstracts
graphs such as scatter plots, conﬁdence intervals and accept-
ability curves. ICEplane and Health Strategy generated very
similar statistics on the initial raw data such as mean, median,
standard deviation and standard error. Bootstrapped statistics
include mean, median, incremental cost effectiveness ratio
(ICER), and 95% conﬁdence intervals. Respective mean ICERs
and conﬁdence intervals between ICEplane and Health Strategy
bootstraps on the three datasets were as follows: ABX: 3771 
(-665, 20,797) vs. 3692 (-1054, 13,303); PIN: -1880 (-412,
2863) vs. -1832 (-333, 25,442) and TCA: -16.48 (-169, 136)
vs. -19.96 (-221, 147). There was good agreement on Fieller’s
conﬁdence intervals. CONCLUSIONS: The ICEplane software
has more statistical and charting features than the Health Strat-
egy bootstrap program. The analyses from Health Strategy ran
more slowly with over 1000 bootstrap replications, but the
results obtained compare reasonably well to ICEplane. The
Health Strategy site has the potential beneﬁts of requiring no
installation and accessibility on multiple computer platforms.
Both of these freeware options should make it easier for indi-
viduals to explore basic bootstrap analyses of cost effectiveness
data, but more comprehensive statistical packages like Stata
should be used when possible.
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OBJECTIVES: Economic evaluations, such as cost effectiveness
analyses (CEA), of pharmaceuticals have historically focused on
costs and consequences at the individual level. However, illness
and individual-level health interventions affect both the individ-
ual and their family members. METHODS: While certain disci-
plines have assessed the cost of illness on multiple family
members and the effects of medical interventions on family
members, CEA has not routinely incorporated measures of effec-
tiveness and costs with the family as the unit of analysis. Family-
level CEA is consistent with recommendations that CEA should
consider everyone affected by the intervention and count all sig-
niﬁcant health outcomes and costs that ﬂow from it, regardless
of who experiences the outcomes or costs. RESULTS: Drawing
from methodologies recommended by the Panel on Cost Effec-
tiveness in Health and Medicine, we explore conceptual and
methodology issues related to estimating costs at the family level
for use in family-level CEA. CONCLUSIONS: We address the
challenges inherent in deﬁning a family, the availability of health
service data to link families, and methods for aggregating, eval-
uating, and comparing family-level costs.
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OBJECTIVES: To ﬁnd the optimal threshold in the cost-
effectiveness analysis in case of co-morbidities. METHODS: The
two-period model was constructed in which agent receives utility
from the income net of medical expenses. Agent can fall ill with
two illnesses in the ﬁrst period. The illnesses are treated and in
case of a success the agent survives to the second period. The
intensity of the treatment (the cost and the survival probability)
is subject to optimization maximizing the total utility. The ill-
nesses may have different morbidities and their occurrence can
be correlated. The relation between the cost of the treatment of
the i-th illness–Ci–and its efﬁciency–Pi–is described by increas-
ing and convex function Ci (Pi). The cases of exogenous and
endogenous budget (the expenses are covered by the insurer 
collecting a fair premium) are analysed. RESULTS: The results
are the same for the exogenous and the endogenous budget 
case. If the illnesses cannot occur together then the optimal
thresholds are the same for both illnesses irrespectively of 
the morbidities, C(P) functions or risk aversion. If the correla-
tion is equal to zero and the C(P) functions are equal then the
illness with higher morbidity will have a higher optimal C/E
threshold. More resources would be allocated to that illness 
both due to the higher morbidity and higher C/E threshold. 
If the correlation is equal to zero and the morbidities are equal
then the illness that is less costly to treat (i.e. always C¢i (Pi) 
< C¢j (Pj)) will have a lower optimal C/E ratio threshold. Similar
results are obtained for positive or slightly negative correlation.
When the correlation is sufﬁciently negative the reversal of 
the above-mentioned phenomena may occur. CONCLUSIONS:
The co-morbidities should be taken into consideration when
specifying the optimal threshold for the ratio in the cost-
effectiveness analysis, even when there is no correlation between
illnesses.
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